Total revenues
Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biktarvy | $3.23B | $3.47B | $3.77B | $3.15B | $3.53B | $3.69B | $3.97B | $3.36B |
| Descovy | $485.00M | $586.00M | $616.00M | $586.00M | $653.00M | $701.00M | $818.00M | $807.00M |
| Trodelvy | — | — | — | $293.00M | $364.00M | $357.00M | $383.00M | $402.00M |
| Yescarta | $414.00M | $387.00M | $389.00M | $386.00M | $393.00M | $349.00M | $367.00M | $332.00M |
| Sofosbuvir/Velpatasvir | — | — | — | $346.00M | $342.00M | $309.00M | $275.00M | $283.00M |
| Genvoya | $440.00M | $449.00M | $470.00M | $364.00M | $377.00M | $377.00M | $380.00M | $264.00M |
| Vemlidy | — | — | — | $252.00M | $252.00M | $280.00M | $286.00M | $237.00M |
| Odefsey | $315.00M | $326.00M | $337.00M | $281.00M | $298.00M | $277.00M | $311.00M | $221.00M |
| Yeztugo | — | — | — | — | — | — | — | $166.00M |
| Veklury | — | — | — | $302.00M | $121.00M | $277.00M | $211.00M | $144.00M |
| Symtuza - Revenue share | — | — | — | $114.00M | $124.00M | $124.00M | $133.00M | $138.00M |
| AmBisome | $151.00M | $130.00M | $108.00M | $139.00M | $129.00M | $123.00M | $118.00M | $138.00M |
| Livdelzi | — | — | — | — | — | — | — | $133.00M |
| Other Liver Disease | — | — | — | $161.00M | $201.00M | $231.00M | $281.00M | $114.00M |
| Tecartus | — | — | — | $78.00M | $92.00M | $83.00M | $91.00M | $75.00M |
| Other HIV | — | — | — | $91.00M | $107.00M | $112.00M | $190.00M | $73.00M |
| Other | $130.00M | $71.00M | $75.00M | $70.00M | $73.00M | $61.00M | $86.00M | $58.00M |
| Royalty, contract and other revenues | $41.00M | $30.00M | $34.00M | $54.00M | $27.00M | $424.00M | $22.00M | $14.00M |
| Total Liver Disease | $832.00M | $733.00M | $719.00M | $758.00M | $795.00M | $819.00M | $845.00M | — |
| Total Oncology | $841.00M | $816.00M | $843.00M | $757.00M | $849.00M | $788.00M | $842.00M | — |
| Total | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.93B | $6.96B |
Segments
Product salesView metric
Royalty, contract and other revenuesView metric
BiktarvyView metric
DescovyView metric
GenvoyaView metric
OdefseyView metric
Symtuza - Revenue shareView metric
YeztugoView metric
Other HIVView metric
Total HIVView metric
LivdelziView metric
Sofosbuvir/VelpatasvirView metric
VemlidyView metric
Other Liver DiseaseView metric
Total Liver DiseaseView metric
VekluryView metric
TecartusView metric
YescartaView metric
Total Cell TherapyView metric
TrodelvyView metric
Total OncologyView metric
AmBisomeView metric
OtherView metric
Total OtherView metric